WCLC 2024 – Pascale Tomasini

You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.

More Information
Unblock content Accept required service and unblock content

Pascale Tomasini discusses the most promising strategies currently being investigated to overcome resistance to PD-(L)1 inhibitors in advanced non-small cell lung cancer, highlights the results of the PIONeeR trial while addressing the ongoing challenges in developing and implementing precision immuno-oncology treatments for PD-(L)1-resistant NSCLC patients.

Here is the full WCLC 2024 report.